GB0202900D0 - Novel formulations of drugs - Google Patents

Novel formulations of drugs

Info

Publication number
GB0202900D0
GB0202900D0 GBGB0202900.7A GB0202900A GB0202900D0 GB 0202900 D0 GB0202900 D0 GB 0202900D0 GB 0202900 A GB0202900 A GB 0202900A GB 0202900 D0 GB0202900 D0 GB 0202900D0
Authority
GB
United Kingdom
Prior art keywords
drugs
novel formulations
formulations
novel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0202900.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laxdale Ltd
Original Assignee
Laxdale Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laxdale Ltd filed Critical Laxdale Ltd
Priority to GBGB0202900.7A priority Critical patent/GB0202900D0/en
Publication of GB0202900D0 publication Critical patent/GB0202900D0/en
Priority to AU2003244454A priority patent/AU2003244454A1/en
Priority to NZ534304A priority patent/NZ534304A/en
Priority to EP03737361A priority patent/EP1478374A1/en
Priority to PCT/GB2003/000490 priority patent/WO2003066071A1/en
Priority to JP2003565495A priority patent/JP2005525329A/ja
Priority to TW092102377A priority patent/TW200404558A/zh
Priority to US10/359,552 priority patent/US6919330B2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0202900.7A 2002-02-07 2002-02-07 Novel formulations of drugs Ceased GB0202900D0 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
GBGB0202900.7A GB0202900D0 (en) 2002-02-07 2002-02-07 Novel formulations of drugs
AU2003244454A AU2003244454A1 (en) 2002-02-07 2003-02-04 Formulations comprising psychotropic drugs and selenium
NZ534304A NZ534304A (en) 2002-02-07 2003-02-04 Formulations comprising psychotropic drugs and selenium
EP03737361A EP1478374A1 (en) 2002-02-07 2003-02-04 Formulations comprising psychotropic drugs and selenium
PCT/GB2003/000490 WO2003066071A1 (en) 2002-02-07 2003-02-04 Formulations comprising psychotropic drugs and selenium
JP2003565495A JP2005525329A (ja) 2002-02-07 2003-02-04 向精神薬とセレンから成る配合物
TW092102377A TW200404558A (en) 2002-02-07 2003-02-06 Novel formulations of drugs
US10/359,552 US6919330B2 (en) 2002-02-07 2003-02-07 Formulations of drugs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202900.7A GB0202900D0 (en) 2002-02-07 2002-02-07 Novel formulations of drugs

Publications (1)

Publication Number Publication Date
GB0202900D0 true GB0202900D0 (en) 2002-03-27

Family

ID=9930626

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0202900.7A Ceased GB0202900D0 (en) 2002-02-07 2002-02-07 Novel formulations of drugs

Country Status (8)

Country Link
US (1) US6919330B2 (enExample)
EP (1) EP1478374A1 (enExample)
JP (1) JP2005525329A (enExample)
AU (1) AU2003244454A1 (enExample)
GB (1) GB0202900D0 (enExample)
NZ (1) NZ534304A (enExample)
TW (1) TW200404558A (enExample)
WO (1) WO2003066071A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050031667A1 (en) * 2003-03-31 2005-02-10 Patel Rajesh A. Implantable polymeric device for sustained release of dopamine agonist
NZ527142A (en) 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
US7071879B2 (en) 2004-06-01 2006-07-04 Ems Technologies Canada, Ltd. Dielectric-resonator array antenna system
FR2873376B1 (fr) * 2004-07-23 2006-11-24 Tetrahedron Sas Nouveaux seleno-hydroxyacides et leurs derives, applications en nutrition, cosmetique et pharmacie
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
ES2519690T3 (es) * 2004-09-24 2014-11-07 University Of Maryland, Baltimore Método de tratamiento de envenenamiento por organosfósforo
WO2006038528A1 (ja) * 2004-10-05 2006-04-13 Inovex Co., Ltd. 精神症状の治療または予防用組成物および方法
US8865763B2 (en) 2005-10-14 2014-10-21 Alltech, Inc. Methods and compositions for altering cell function
TWI319708B (en) * 2005-10-14 2010-01-21 Methods and compositions for altering cell fuction
US8871715B2 (en) 2005-10-14 2014-10-28 Alltech, Inc. Use of selenium compounds, especially selenium yeasts for altering cognitive function
WO2007109851A1 (en) 2006-03-29 2007-10-04 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
CA2650309C (en) * 2006-04-24 2014-08-19 Alltech, Inc. Selenium-containing compositions and use of the same
WO2008119109A1 (en) * 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
WO2009043106A1 (en) * 2007-10-03 2009-04-09 Velacor Therapeutics Pty Ltd Inorganic selenium and angiogenesis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090414A (en) * 1970-05-20 2000-07-18 Life Science Labs, Inc. Method and composition to reduce cancer incidence
SE7812170L (sv) * 1977-12-07 1979-06-08 Klippan Nv Belteslas med lett frigorbar sperr
AT397200B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung von selenmethionin zur herstellung eines arzneimittels
IL110139A0 (en) 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
US5358720A (en) 1993-10-22 1994-10-25 Koppel Richard M Treatment of arthritic conditions
HUT72422A (en) 1994-04-20 1996-04-29 Beres Export Import Rt Aquous concentrate and process for its preparation
FR2737205B1 (fr) * 1995-07-26 1997-09-12 Oreal Nouveaux derives de n,n'-di(aralkyl) n,n'-di(2-azaaralkyl) alkylene diamine et leur utilisation dans des compositions pharmaceutiques et cosmetiques
US6077828A (en) 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
AU7222598A (en) * 1997-04-29 1998-11-24 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
US6399114B2 (en) 2000-05-26 2002-06-04 C & D Foreman, Inc. Nutritional system for nervous system disorders
DK1163904T3 (da) 2000-06-16 2006-08-14 Matthias Dr Med Rath Sammensætning til forebyggelse af glat muskelsygdom, der omfatter ascorbat, arginin og magnesium

Also Published As

Publication number Publication date
US6919330B2 (en) 2005-07-19
NZ534304A (en) 2006-07-28
WO2003066071A8 (en) 2006-08-17
AU2003244454A1 (en) 2003-09-02
EP1478374A1 (en) 2004-11-24
WO2003066071A1 (en) 2003-08-14
TW200404558A (en) 2004-04-01
JP2005525329A (ja) 2005-08-25
US20030175361A1 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
IL164519A0 (en) Pharmaceutical formulations
PL375833A1 (en) Pharmaceutical formulations of modafinil
AU2003296897A8 (en) Pharmaceutical formulations of camptothecine derivatives
GB0319041D0 (en) Pharmaceutical Formulations
GB0302671D0 (en) Pharmaceutical formulations
PL1615622T3 (pl) Preparaty doksycyklin do jednorazowego dziennego podawania
AU2003279911A8 (en) Therapeutic formulations
IL172824A0 (en) Pharmaceutical formulations
GB0121715D0 (en) Pharmaceutical formulations
HUP0303948A2 (hu) Szájban diszpergálódó szilárd gyógyszerforma
GB2392093B (en) Pharmaceutical formulations
GB0202900D0 (en) Novel formulations of drugs
GB2380129B (en) Pharmaceutical formulations
GB0120701D0 (en) Pharmaceutical formulations
GB0302672D0 (en) Pharmaceutical formulations
SI1556026T1 (sl) Nove farmacevtske formulacije modafinila
GB0103638D0 (en) Pharmaceutical formulations
IL166337A0 (en) Oral administration of calctionin
GB0229258D0 (en) Medicinal compositions
GB0105560D0 (en) Pharmaceutical formulations
GB0316341D0 (en) Pharmaceutical formulations
AU2003295846A8 (en) Pharmaceutical formulations of celcoxib
EP1480649A4 (en) STABLE PHARMACEUTICAL COMPOSITIONS
AU2003298725A8 (en) Preparation of metallotexaphyrins
GB0327742D0 (en) Novel uses of known drugs

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)